All Stories

  1. Clinical characteristics and management of patients with secondary hyperparathyroidism undergoing hemodialysis: a feasibility analysis of electronic health records using Natural Language Processing
  2. Bone Marrow–Derived RIPK3 Mediates Kidney Inflammation in Acute Kidney Injury
  3. Curcumin reduces acute kidney injury and ferroptosis
  4. Advances in understanding the role of angiotensin-regulated proteins in kidney diseases
  5. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease – A systematic literature review by a European panel of experts
  6. Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression
  7. Correction: Mas, S., et al. Identification and Chemical Characterization of Insoluble Contaminants in Hemodialysis Water Treatment. Water 2018, 10, 486
  8. Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD)
  9. Identification and Chemical Characterization of Insoluble Contaminants in Hemodialysis Water Treatment
  10. Fabry disease revisited: Management and treatment recommendations for adult patients
  11. Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields
  12. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
  13. Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease
  14. Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease
  15. Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation
  16. Enzyme Replacement Therapy for Fabry Disease
  17. Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms
  18. Atrial fibrillation in chronic kidney disease
  19. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling
  20. Hypertension in Chronic Kidney Disease Part 1
  21. Hypertension in Chronic Kidney Disease Part 2
  22. Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury
  23. Histone lysine crotonylation during acute kidney injury in mice
  24. Atherosclerotic renal artery stenosis in the post-CORAL era part 1: the renal penumbra concept and next-generation functional diagnostic imaging
  25. Atherosclerotic renal artery stenosis in the post-CORAL era part 2: new directions in Transcatheter Nephron Salvage following flawed revascularization trials
  26. Clinical management of the uraemic syndrome in chronic kidney disease
  27. Corrigendum to “IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes” [Biochim. Biophys. Acta 1853 (12) (2015) 3224–3234]
  28. NFκBiz protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells
  29. Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events
  30. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients
  31. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial
  32. Cómo debemos analizar y describir la mortalidad de nuestros pacientes: experiencia del Grupo Centro Diálisis Peritoneal
  33. The inflammatory cytokine TWEAK decreases PGC-1α expression and mitochondrial function in acute kidney injury
  34. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
  35. Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: predictors of patient prognosis?
  36. Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants
  37. IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes
  38. The fate of triaged and rejected manuscripts
  39. Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances
  40. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered
  41. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition
  42. Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes
  43. The double challenge of resistant hypertension and chronic kidney disease
  44. CD74 in Kidney Disease
  45. Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification
  46. Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes
  47. Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate
  48. Phosphodiesterase type 5 inhibitors and kidney disease
  49. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  50. Timing of eculizumab therapy for C3 glomerulonephritis
  51. Lyso-Gb3 activates Notch1 in human podocytes
  52. Decreasing incidence of renal replacement therapy over time at the critical 50–59-year age range suggests a role for nephroprotective therapy in ADPKD
  53. Humble kidneys predict mighty heart troubles
  54. Translational value of animal models of kidney failure
  55. Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function
  56. 2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs
  57. Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research
  58. Modifiable Risk Factors for Increased Arterial Stiffness in Outpatient Nephrology
  59. Designing drugs that combat kidney damage
  60. TNF-related weak inducer of apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells via canonical NF-κB pathway and ERK activation
  61. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease
  62. Biocompatibility Reduces Inflammation-Induced Apoptosis in Mesothelial Cells Exposed to Peritoneal Dialysis Fluid
  63. Angiotensin II, via angiotensin receptor type 1/nuclear factor-κB activation, causes a synergistic effect on interleukin-1-β-induced inflammatory responses in cultured mesangial cells
  64. Association between the IL17RA rs4819554 polymorphism and reduced renal filtration rate in the Spanish RENASTUR cohort
  65. Albumin-induced apoptosis of tubular cells is modulated by BASP1
  66. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies
  67. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis
  68. Healthcare-associated infections: new challenges looking for answers
  69. Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology
  70. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides
  71. Welcome to the new ckj: an open-access resource integrating clinical, translational and educational research into clinical practice
  72. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  73. Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells
  74. TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2
  75. The C-Terminal Module IV of Connective Tissue Growth Factor, Through EGFR/Nox1 Signaling, Activates the NF-κB Pathway and Proinflammatory Factors in Vascular Smooth Muscle Cells
  76. CKD hotspots around the world: where, why and what the lessons are. A CKJ review series
  77. Bicarbonate therapy, phosphate binders, and risk for vascular calcification
  78. Erratum
  79. Peritoneal Dialysis Can Be an Option for Dominant Polycystic Kidney Disease: an Observational Study
  80. Cortisol levels are associated with mortality risk in hemodialysis patients
  81. Klotho Prevents NFκB Translocation and Protects Endothelial Cell From Senescence Induced by Uremia
  82. Urine 2DE proteome analysis in healthy condition and kidney disease
  83. Galectin-3, a Biomarker Linking Oxidative Stress and Inflammation With the Clinical Outcomes of Patients With Atherothrombosis
  84. IL-17A is a novel player in dialysis-induced peritoneal damage
  85. Deferasirox nephrotoxicity—the knowns and unknowns
  86. Application of the New Cholesterol Guidelines
  87. Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation
  88. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians
  89. CXCL16 in kidney and cardiovascular injury
  90. Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis
  91. Next-Generation Phosphate Binders: Focus on Iron-Based Binders
  92. Therapeutic approaches to diabetic nephropathy—beyond the RAS
  93. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure
  94. The Authors Reply:
  95. Osteoprotegerin and kidney disease
  96. TWEAK Promotes Peritoneal Inflammation
  97. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy
  98. Molecular mediators of favism-induced acute kidney injury
  99. Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells
  100. TWEAK and the progression of renal disease: clinical translation
  101. Role of chemokines in proteinuric kidney disorders
  102. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis
  103. Gremlin Activates the Smad Pathway Linked to Epithelial Mesenchymal Transdifferentiation in Cultured Tubular Epithelial Cells
  104. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease
  105. Increasing serum calcium levels and recent return from transplantation as clues to the tuberculous nature of refractory peritoneal dialysis peritonitis
  106. Individualization of Dialysate Calcium Concentration According to Baseline Pre-Dialysis Serum Calcium
  107. Mitochondria-targeted therapies for acute kidney injury
  108. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease
  109. Hyperlipidemia-Associated Renal Damage Decreases Klotho Expression in Kidneys from ApoE Knockout Mice
  110. 3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes
  111. Fn14 in podocytes and proteinuric kidney disease
  112. TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation
  113. Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF-κB-mediated inflammatory responses in kidney tubular cells
  114. Subclinical versus overt obesity in dialysis patients: more than meets the eye
  115. p-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells
  116. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast
  117. The demise of calcium-based phosphate binders
  118. Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry
  119. Unilateral ureteral obstruction: beyond obstruction
  120. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?
  121. A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort
  122. Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis
  123. HCV Infection and Miravirsen
  124. Osteoprotegerin in Exosome-Like Vesicles from Human Cultured Tubular Cells and Urine
  125. Connective tissue growth factor is a new ligand of epidermal growth factor receptor
  126. Identification of a Potent Endothelium-Derived Angiogenic Factor
  127. Two independent pathways of regulated necrosis mediate ischemia–reperfusion injury
  128. Macrophages and Recently Identified Forms of Cell Death
  129. Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema
  130. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response
  131. Parathyroid hormone–related protein protects renal tubuloepithelial cells from apoptosis by activating transcription factor Runx2
  132. Progress in the development of animal models of acute kidney injury and its impact on drug discovery
  133. Klotho to Treat Kidney Fibrosis
  134. Pulmonary Hypertension in CKD
  135. Laser Therapy in Metabolic Syndrome‐Related Kidney Injury
  136. MIF, CD74 and other partners in kidney disease: Tales of a promiscuous couple
  137. A Polymeric Nanomedicine Diminishes Inflammatory Events in Renal Tubular Cells
  138. A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI
  139. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+T and NK cells
  140. Fibrosis: a key feature of Fabry disease with potential therapeutic implications
  141. TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease
  142. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice
  143. Klotho, phosphate and inflammation/ageing in chronic kidney disease
  144. Vitamin D receptor activation and cardiovascular disease
  145. A role for the membrane proteome in human chronic kidney disease erythrocytes
  146. Klotho modulates the stress response in human senescent endothelial cells
  147. Uromodulin, Inflammasomes, and Pyroptosis
  148. Inflammatory Cytokines and Survival Factors from Serum Modulate Tweak-Induced Apoptosis in PC-3 Prostate Cancer Cells
  149. Notch3 and kidney injury: never two without three
  150. The use of echocardiography in observational clinical trials: the EURECA-m registry
  151. Fabry disease: the many faces of a single disorder
  152. Is it or is it not a pathogenic mutation? Is it or is it not the podocyte?
  153. Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
  154. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats
  155. Phosphate: a stealthier killer than previously thought?
  156. Targeting chemokines in proteinuria-induced renal disease
  157. Angiotensin II Contributes to Renal Fibrosis Independently of Notch Pathway Activation
  158. AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
  159. TWEAK (tumor necrosis factor–like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation
  160. High prevalence of winter 25-hydroxyvitamin D deficiency despite supplementation according to guidelines for hemodialysis patients
  161. Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?
  162. Implementation of proteomic biomarkers: making it work
  163. Dual-Specificity Phosphatases Are Implicated in Severe Hyperplasia and Lack of Response to FGF23 of Uremic Parathyroid Glands from Rats
  164. Monocyte subpopulations and cardiovascular risk in chronic kidney disease
  165. GSK3, Snail, and Adhesion Molecule Regulation by Cyclosporine A in Renal Tubular Cells
  166. Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus
  167. Proteome changes in the myocardium of experimental chronic diabetes and hypertension
  168. The Human Plasma Lipidome
  169. Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy
  170. Undetectable serum calcidiol: not everything that glitters is gold
  171. HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II
  172. Gremlin Is a Downstream Profibrotic Mediator of Transforming Growth Factor-Beta in Cultured Renal Cells
  173. Risk in Dosing Regimens for 25-OH Vitamin D Supplementation in Chronic Haemodialysis Patients
  174. Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
  175. Haematuria: the forgotten CKD factor?
  176. Oxidative Stress, Macrophage Infiltration and CD163 Expression Are Determinants of Long-Term Renal Outcome in Macrohematuria-Induced Acute Kidney Injury of IgA Nephropathy
  177. Phosphorus and Nutrition in Chronic Kidney Disease
  178. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy
  179. AKI Associated with Macroscopic Glomerular Hematuria: Clinical and Pathophysiologic Consequences
  180. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis
  181. TWEAK, a multifunctional cytokine in kidney injury
  182. Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?
  183. Delayed Graft Function and Cotrimoxazole
  184. The Inflammatory Cytokines TWEAK and TNF  Reduce Renal Klotho Expression through NF B
  185. Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow—implications for CKD and cardiovascular disease
  186. Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?
  187. Glomerulonefritis: concepto y clasificación. Etiopatogenia de las glomerulonefritis
  188. Major pathways of the reno–cardiovascular link: the sympathetic and renin–angiotensin systems
  189. The complexity of the cardio–renal link: taxonomy, syndromes, and diseases
  190. The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda
  191. The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?
  192. Eficacia de la suplementación oral intradiálisis en pacientes con insuficiencia renal crónica
  193. Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for
  194. Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK
  195. The meaning of urinary creatinine concentration
  196. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients
  197. Soluble TWEAK and PTX3 in Nondialysis CKD Patients: Impact on Endothelial Dysfunction and Cardiovascular Outcomes
  198. Paricalcitol for reduction of albuminuria in diabetes
  199. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications
  200. Animal Models of Cardiovascular Diseases
  201. Calcific uremic arteriolopathy while on cinacalcet
  202. Tenofovir Nephrotoxicity: 2011 Update
  203. Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease
  204. Statins Inhibit Angiotensin II/Smad Pathway and Related Vascular Fibrosis, by a TGF-β-Independent Process
  205. Peritonitis Due to Microbacterium sp in a Patient on Cycler Peritoneal Dialysis
  206. Familial C4B deficiency and immune complex glomerulonephritis
  207. New paradigms in cell death in human diabetic nephropathy
  208. Unravelling fibrosis: two newcomers and an old foe
  209. Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry
  210. Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury
  211. NF- B in Renal Inflammation
  212. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy
  213. 'Reality and desire' in the care of advanced chronic kidney disease
  214. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage
  215. The expanding spectrum of biological actions of vitamin D
  216. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy
  217. UGA hopping: a sport for nephrologists too?
  218. Caspase-12 and Diabetic Nephropathy: From Mice to Men?
  219. Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
  220. Local Non-Esterified Fatty Acids Correlate With Inflammation in Atheroma Plaques of Patients With Type 2 Diabetes
  221. Suppressors of Cytokine Signaling Abrogate Diabetic Nephropathy
  222. TWEAK Activates the Non-Canonical NFκB Pathway in Murine Renal Tubular Cells: Modulation of CCL21
  223. BASP1 Promotes Apoptosis in Diabetic Nephropathy
  224. BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure
  225. Regulation of Vascular and Renal Cells by Common Mediators in Health and Disease: Role of the Renin—Angiotensin System in the Pathophysiology of Hypertension and Cardiovascular Disease
  226. TNF Superfamily: A Growing Saga of Kidney Injury Modulators
  227. Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis
  228. Detection of lfrA and tap efflux pump genes among clinical isolates of non-pigmented rapidly growing mycobacteria
  229. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
  230. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes
  231. Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease
  232. Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout Mice
  233. Estrategias en la profilaxis y el tratamiento de la malnutrición en diálisis peritoneal: un problema infradiagnosticado
  234. A Nanoconjugate Apaf-1 Inhibitor Protects Mesothelial Cells from Cytokine-Induced Injury
  235. 2nd Combined Working Group and Management Committee Meeting of Urine and Kidney Proteomics COST Action 29-30 March 2009, Nafplio, Greece
  236. Inhibition of p38-MAPK Potentiates Cisplatin-Induced Apoptosis via GSH Depletion and Increases Intracellular Drug Accumulation in Growth-Arrested Kidney Tubular Epithelial Cells
  237. Considering TWEAK as a target for therapy in renal and vascular injury
  238. Patogénesis de la malnutrición en pacientes en diálisis con énfasis en los aspectos más específicos de la diálisis peritoneal
  239. TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis
  240. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells
  241. CTGF Promotes Inflammatory Cell Infiltration of the Renal Interstitium by Activating NF- B
  242. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia
  243. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations
  244. Additive Effects of Soluble TWEAK and Inflammation on Mortality in Hemodialysis Patients
  245. Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity
  246. Essential Role of TGF-β/Smad Pathway on Statin Dependent Vascular Smooth Muscle Cell Regulation
  247. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients
  248. Gliotoxin Inhibits Neointimal Hyperplasia after Vascular Injury in Rats
  249. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation
  250. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis
  251. Mechanisms of Renal Apoptosis in Health and Disease
  252. A search for cyclophilin-A gene variants in cyclosporine A-treated renal transplanted patients
  253. ACE gene polymorphism and the prognosis and treatment of overt diabetic nephropathy
  254. Pharmacological Modulation of Epithelial Mesenchymal Transition Caused by Angiotensin II. Role of ROCK and MAPK Pathways
  255. A Slit in Podocyte Death
  256. 3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization
  257. Severe everolimus-associated pneumonitis in a renal transplant recipient
  258. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults
  259. Benefits of preserving residual renal function in peritoneal dialysis
  260. The Cytokine TWEAK Modulates Renal Tubulointerstitial Inflammation
  261. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy
  262. The Death Ligand TRAIL in Diabetic Nephropathy
  263. Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
  264. TWEAKing renal injury
  265. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation
  266. Emphysematous Pyelonephritis in Dialysis Patient After Embolization of Failed Allograft
  267. Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis
  268. Endovascular repair of mycotic aneurysms of the aorta: An alternative to conventional bypass surgery in patients with acute sepsis
  269. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis
  270. Cytokine cooperation in renal tubular cell injury: The role of TWEAK
  271. 3,4-DGE is Important for Side Effects in Peritoneal Dialysis What About its Role in Diabetes
  272. Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy--a Spanish multicentre experience
  273. Peritoneal defence--lessons learned which apply to diabetes complications
  274. Fn14 Is Upregulated in Cytokine-Stimulated Vascular Smooth Muscle Cells and Is Expressed in Human Carotid Atherosclerotic Plaques: Modulation by Atorvastatin
  275. Lethal activity of FADD death domain in renal tubular epithelial cells
  276. 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis
  277. Angiotensin II and Reactive Oxygen Species
  278. Long-Term Blood Pressure Control Prevents Oxidative Renal Injury
  279. 3,4-Dideoxyglucosone-3-ene Induces Apoptosis in Renal Tubular Epithelial Cells
  280. Soporte nutricional en la insuficiencia renal crónica
  281. Role of Bcl-xL in paracetamol-induced tubular epithelial cell death
  282. Modulation of survival in osteoblasts from postmenopausal women
  283. Tight blood pressure control decreases apoptosis during renal damage
  284. Paracetamol-Induced Renal Tubular Injury: A Role for ER Stress
  285. Intracellular Mechanisms of Cyclosporin A-Induced Tubular Cell Apoptosis
  286. Targeting apoptosis in acute tubular injury
  287. Bcl-xL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells
  288. Regulation of apoptosis by lethal cytokines in human mesothelial cells
  289. Staining for cell death
  290. Role of Endogenous Vascular Endothelial Growth Factor in Tubular Cell Protection Against Acute Cyclosporine Toxicity1
  291. Pseudomonas oryzihabitans peritonitis in a patient on continuous ambulatory peritoneal dialysis
  292. Renal cell loss through cell suicide
  293. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure
  294. The Fas ligand/Fas system in renal injury
  295. Role of cytokines in the response to erythropoietin in hemodialysis patients
  296. Hepatitis B Virus Infection
  297. Circulating Endothelial Cells in Sickle Cell Anemia
  298. Epithelial differentiation of metanephric mesenchymal cells after stimulation with hepatocyte growth factor or embryonic spinal cord.
  299. Cefazolin-Induced Neurotoxicity
  300. Effect of Recombinant Human Growth Hormone in a Postpediatric Hemodialysis Patient with Delayed Growth
  301. Presence of circulating antibodies against brush border antigens (FxlA) in a patient with membranous nephropathy and bilateral pyeloureteral stenosis. Comparison with idiopathic membranous nephropathy
  302. Salmonella enteritidis empyema complicating lupus pleuritis.
  303. Involvement of Lipid Mediators in the Pathogenesis of Experimental Nephrosis in Rats: Its Pharmacological Modulation
  304. Role of platelet-activating factor in adriamycin-induced nephropathy in rats
  305. Apoptosis in the Kidney
  306. Nephrotoxicity